MIAI-ATRPred

Anti-tumour necrosis factor Treatment Response Predictor

The Problem

Non-responding rheumatoid arthritis patients to conventional DMARDs drugs are invariably put on costly biologics (anti-TNF) treatments leading to about one-third patients not responding. These non-responding patients live at high disease activity for at least 6 months, when they are labeled as non-responders and given different targeted treatments. Further, in contrast to US and India, UK uses almost a double cut-off for disease activity to start the biologic treatment as the anti-TNF therapy are costly and rated as one of the highest grossing drugs in the market. Despite a lot of research going on in the area, there is no commercially available test to predict response to anti-TNF treatment, available to clinicians.

Our Solution

Watch the short explainer video



Value Proposition

We propose a simple prognostic blood test that is predictive of the anti-TNF therapy response with 81% accuracy (highest as per our literature search). The test hopes to aid the clinicians in decision making, whether to put the patients on anti-TNF therapy or start a different target therapy, thus saving a lot of cost & time.



RA Patients

At least 1% of population suffers from RA. Anti-TNF therapy is given invariably to RA patients, which leads to one-third non-responders. Non-responding RA patients are worst sufferer as they live with high disease activity for 6 months, which causes more erosion in joints. Further, the anti-TNF drugs over the period of 6 months become very expensive. With this predictive test for anti-TNF response, they will be saving a lot of time as well as cost and will be rescued from living a very poor quality of life.



Rheumatology Consultants

Presently, clinicians empirically put their patients under anti-TNF therapy. Our test will aid them in decision-making and allow them to use different treatment regimens for the patients predicted to be non-responder, so that they can bring the disease inflammation under control and offer a better disease management to their patients.